Novo Nordisk said it remains confident in the benefit-risk profile of our GLP-1 medicines when used consistent with their indications and product labeling. But neither directly addressed a link between GLP-1 drugs and an altered sense of smell
for example, you might pay 20% of the price of Saxenda
RELATED CONTENT Oral GLP-1s are set to shake up the weight-loss drug market, with Foundayo, launched by Eli Lilly in early April, already making waves across the U.S
doi: 10.1016/j.cbi.2022.109958 75 SalvoliniEBuldreghiniELucariniGVigniniALenziADi PrimioRet al
54 PickartL.Vasquez-SolteroJ.MargolinaA
Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which typically diminish over time with continued use and gradual dose escalation